

Dear Valued Partner,

You are receiving this letter as you have been identified as a business partner (e.g. contingent workers, contractor, vendor, service provider) for Hoffmann-La Roche Limited ("Roche"), including its divisions of Pharma, Diagnostics and Diabetes Care. Roche is committed to providing a safe environment for employees, contingent workers, visitors, customers, patients and third party vendors. As a leading innovative healthcare company, we believe in science, the benefit of vaccines, and their safe and effective use in the fight against COVID-19. Vaccines, paired with other safety measures such as physical distancing, wearing masks, and COVID-19 testing, are the safest and most effective tools against spread of the virus, and are the best possible protection from severe disease, hospitalization and death.

After careful consideration, we have made the decision that being fully vaccinated will be a condition for individuals seeking access to the Campus or any other Company site or location where Company business or activity is occurring.

Starting on **January 4**th **2022**, you or any of your employees, representatives, including subcontractors ("Representatives") providing services at any sites, including Roche's customers' sites, when providing services from Canada on behalf of Roche ("Sites") for any reason, **must be Fully Vaccinated**. "Fully vaccinated" means a state of being 14 days after having received the completed series of an accepted vaccine or combination of accepted vaccines (e.g., two doses of a two-dose vaccine series, or one dose of a single-dose vaccine series accepted by Health Canada) and, as applicable, after having received any additional doses of an accepted vaccine (i.e., booster shots) - if and when such additional doses are required and approved by Health Canada and the applicable provincial health authority.

The expectation is that you and your Representatives will maintain full vaccination status (including "booster" shots, if required in the future) at all times throughout your engagement with Roche until further notice. We may require those accessing the Sites to provide proof of vaccination. If Representatives cannot present a valid proof of vaccination or are not Fully Vaccinated, they are at risk of being turned away at the Site entrance. This does not include those individuals that have a valid specific medical exemption or other valid protected grounds under applicable human rights legislation who must provide Roche with a negative rapid antigen test or PCR result within the last 72-hours.

We believe this is the best way for us to protect our operations and to supply healthcare solutions and services for patients in Canada.

Tel ./ Tél.: 905-542-5555

Fax /Téléc.: 905-542-7130

www.rochecanada.com



We thank you for your support of this important infection prevention and control policy with your team.

If you have any questions, please contact canada.vaccination@roche.com.

Kind Regards,

Ronnie Miller President & CEO

Hoffmann -La Roche Ltd

Andrew N. Plank President & General Manager

Roche Diagnostics division

Jade Dagher Cluster Head, Northwestern Europe & Canada

Roche Diabetes Care division

www.rochecanada.com

Tel ./ Tél.: 905-542-5555

Fax /Téléc.: 905-542-7130